Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Dopamine Agonists: Their Role in the Treatment of Parkinson's Disease
JNNP 68;685-690, Brooks,D.J., 2000
Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Schizophrenia as a Brain Disease, The Dopamine Receptor Story
Arch Neurol 50:1093-1095, 10971993., Seeman,P., 1993
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989
Postmortem Analysis of Adrenal-Medulla-to-Caudate Autograft in a Patient with Parkinson's Disease
Ann Neurol 25:607-614, Hurtig,H.,et al, 1989
Dopamine D2 Receptor Density Remains Constant in Treated Parkinson's Disease
Ann Neurol 19:487-492, Guttman,M.,et al, 1986